Gapping up
In reaction to strong earnings/guidance: KORS +7.8%, ZOES +3.6%, CBRL +3.0%, ATHM +2.9%, INNL +2.6%, NCS+1.2%, NX +0.9%, HBI +0.8%
M&A news: DWRE +56.4% (to be acquired by Salesforce (CRM) for $75.00/share in cash), PACB +3.7% (cont strength following yday's M&A rumors), PSEC +0.1% (sells its interests in Harbortouch Payments to Searchlight Capital Partners)
Select metals/mining stocks trading higher:AU +3.5%, GFI +2.8%, SWC +2.5%, ABX +2.2%, CLF +2.1%, AUY +1.9%,GDX +1.6%, GOLD +1.3%, NEM +1.3%.
Other news: PARN +17% (commences a Contract Manufacturing Agreement with Merial, the animal health division of Sanofi (SNY)), GALE +16.6% (FDA has designated NeuVax, combined with recombinant granulocyte macrophage-colony stimulating factor, as a Fast Track development program for the treatment of patients with early stage breast cancer), ATNM +11.4% (announces 'positive' results from its Phase 1 Actimab-A trial in patients newly diagnosed with acute myeloid leukemia), AVEO+8.8% (Growth Equity Opportunities discloses 29.6% active stake), CANF +8% (reaches agreement with EMA on Pivotal Phase III clinical trial with Piclidenoson (CF101) in Rheumatoid Arthritis), CJES +7.5% (enters into forbearance agreement in connection with previously announced covenant violation, lenders agree to forbear from exercising default remedies or accelerating any indebtedness through June 30), PRQR +1.9% (announces that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10), RGLS+1.3% (expands clinical trial collaboration with GSK), SRPT +1.2% (after BioMarin (BMRN) withdraws its Kyndrisa Marketing Authorization Application from the European Medicines Agency), JCP +1.2% (to refinance & extend maturity date of its $2.25 bln senior secured term loan facility), .
Analyst comments: WFM +2.8% (upgraded to Outperform from Neutral at Credit Suisse), CCE +1.6% (initiated with a Buy at BofA/Merrill), COST +1.2% (upgraded to Buy from Neutral at Goldman), INXN +1% (upgraded to Outperform from Market Perform at Wells Fargo), FOXA +0.9% (added to US 1 List at BofA/Merrill), RLYP +0.5% (upgraded to Neutral from Underperform at Mizuho)
In reaction to strong earnings/guidance: KORS +7.8%, ZOES +3.6%, CBRL +3.0%, ATHM +2.9%, INNL +2.6%, NCS+1.2%, NX +0.9%, HBI +0.8%
M&A news: DWRE +56.4% (to be acquired by Salesforce (CRM) for $75.00/share in cash), PACB +3.7% (cont strength following yday's M&A rumors), PSEC +0.1% (sells its interests in Harbortouch Payments to Searchlight Capital Partners)
Select metals/mining stocks trading higher:AU +3.5%, GFI +2.8%, SWC +2.5%, ABX +2.2%, CLF +2.1%, AUY +1.9%,GDX +1.6%, GOLD +1.3%, NEM +1.3%.
Other news: PARN +17% (commences a Contract Manufacturing Agreement with Merial, the animal health division of Sanofi (SNY)), GALE +16.6% (FDA has designated NeuVax, combined with recombinant granulocyte macrophage-colony stimulating factor, as a Fast Track development program for the treatment of patients with early stage breast cancer), ATNM +11.4% (announces 'positive' results from its Phase 1 Actimab-A trial in patients newly diagnosed with acute myeloid leukemia), AVEO+8.8% (Growth Equity Opportunities discloses 29.6% active stake), CANF +8% (reaches agreement with EMA on Pivotal Phase III clinical trial with Piclidenoson (CF101) in Rheumatoid Arthritis), CJES +7.5% (enters into forbearance agreement in connection with previously announced covenant violation, lenders agree to forbear from exercising default remedies or accelerating any indebtedness through June 30), PRQR +1.9% (announces that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10), RGLS+1.3% (expands clinical trial collaboration with GSK), SRPT +1.2% (after BioMarin (BMRN) withdraws its Kyndrisa Marketing Authorization Application from the European Medicines Agency), JCP +1.2% (to refinance & extend maturity date of its $2.25 bln senior secured term loan facility), .
Analyst comments: WFM +2.8% (upgraded to Outperform from Neutral at Credit Suisse), CCE +1.6% (initiated with a Buy at BofA/Merrill), COST +1.2% (upgraded to Buy from Neutral at Goldman), INXN +1% (upgraded to Outperform from Market Perform at Wells Fargo), FOXA +0.9% (added to US 1 List at BofA/Merrill), RLYP +0.5% (upgraded to Neutral from Underperform at Mizuho)